bearish
Innovent Biologics (信达生物) Post IPO: Hit Our TP, What's Next?
517 Views01 Nov 2018 14:21
Innovent Biologics was priced at the high end and it started trading yesterday (November 1st). It traded up by 18.5% on the first day and 8% on the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- ECM Weekly (27 April 2019) - Luckin, Duiba, Leong Hup, ARA US Hosp, Douyu, So-Young, Yunji27 Apr 2019
- ECM Weekly (18 April 2019) - Duiba Group, MabPharm, Huami, Cofco Meat, Innovent, Times China18 Apr 2019
- Innovent Biologics (信达生物) Placement - Selling upon Lock-Up Expiry16 Apr 2019
- Innovent Biologics (信达生物) Post IPO: Hit Our TP, What's Next?01 Nov 2018
- Innovent Biologics (信达生物) IPO: Limited Upside Despite Strong Cornerstones (Part 3)16 Oct 2018
- Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)10 Oct 2018
x